Novo Nordisk, a global healthcare company, has launched Ozempic® (injectable semaglutide) in India. Ozempic® is a once-weekly GLP-1 receptor agonist approved for adults with type 2 diabetes, to be used along with diet and exercise.
The launch comes at a critical time. India has over 101 million people living with diabetes, according to World Health Organization estimates. The country also has a large population with prediabetes and obesity, increasing the risk of heart and kidney complications.
Ozempic® helps people with type 2 diabetes control blood sugar levels while also supporting clinically proven weight loss. In addition to improving HbA1c, the treatment offers cardiovascular and kidney protection, making it a comprehensive diabetes care option.
Key Benefits of Ozempic®
- Strong and sustained HbA1c reduction
- Clinically proven weight-loss benefits
- Suitable for patients with high cardiovascular risk
- Helps reduce major heart-related events
- Slows the progression of kidney disease
Speaking about the launch, Vikrant Shrotriya, Managing Director, Novo Nordisk India, said the introduction of Ozempic® marks a major step forward in diabetes care. He added that the therapy gives doctors and patients an effective, easy-to-use option that delivers long-term health benefits through a simple once-weekly injection.
How Ozempic® Works
Ozempic® belongs to the GLP-1 class of medicines. It works by:
- Improving insulin response
- Lowering blood sugar levels
- Reducing appetite and food intake
- Supporting healthy weight loss
- Lowering heart and kidney risks linked to diabetes
Ozempic® has been developed by Novo Nordisk over more than 20 years of research and is backed by 38 million patient-years of global clinical use. Semaglutide is also included in the WHO Model List of Essential Medicines, highlighting its global importance in diabetes care.
In India, Ozempic® is available in 0.25 mg, 0.5 mg, and 1 mg doses, delivered through the FlexTouch® pen, designed for ease, accuracy, and comfort.
